Showing results (31-40 of 77) with videos related to

Sort By:
Pageof 8
Bioconjugate Chemistry|November 18, 2004
A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifierKuo-Shyan Lin, Andrew Luu, Kwamena E Baidoo, et al.
Investigational New Drugs|November 5, 2010
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortiumAjjai Alva, Susan Slovin, Stephanie Daignault, et al.
Cancers|August 14, 2025
A Comparison of In-Person and Telehealth Personalized Exercise Programs for Cancer Survivors: A Secondary Data AnalysisNada Lukkahatai, Gyumin Han, Chitchanok Benjasirisan, et al.
Biomedicines|November 25, 2023
Feasibility of DNA Methylation Age as a Biomarker of Symptoms and Resilience among Cancer Survivors with Multiple Chronic ConditionsNada Lukkahatai, Jongmin Park, Hejingzi Monica Jia, et al.
Cancer Treatment Reviews|April 6, 2021
High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic reviewSophie L Gerritse, Jorien B E Janssen, Mariette Labots, et al.
Molecular Oncology|April 4, 2017
The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasionAnup Sharma, Janet Mendonca, James Ying, et al.
The Prostate|July 13, 2011
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancerDaniel J Zabransky, Heath A Smith, Christopher J Thoburn, et al.
Lancet (London, England)|March 1, 2011
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyKarim Fizazi, Michael Carducci, Matthew Smith, et al.
European Urology|December 3, 2014
Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate CancerKarim Fizazi, Christophe Massard, Matthew Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology GroupRobert Gray, Judith Manola, Scott Saxman, et al.
Pageof 8